Literature DB >> 32293122

Engineered Ovarian Cancer Cell Lines for Validation of CAR T Cell Function.

Claire E Repellin1, Priya Ganesan1, Javier F Alcudia2, Haritha K Duggireddy Lakshmireddy2, Puja Patel1, Lucia Beviglia1, Harold S Javitz3, Lidia Sambucetti1, Parijat Bhatnagar1.   

Abstract

A set of genetically engineered isogenic cell lines is developed to express either folate receptor alpha or mesothelin, and a control cell line negative for both antigens. These cell lines also express fluorescent and bioluminescent reporter transgenes. The cell lines are used to authenticate specificity and function of a T-cell biofactory, a living vector that is developed to express proportionate amounts of engineered proteins upon engaging with disease cells through their specific antigenic biomarkers. The engineered cell lines are also used to assess the cytolytic function and specificity of primary T cells engineered with chimeric antigen receptors; and the specificity of monoclonal antibodies. The strategy described can be used to generate other cell lines to present different disease-specific biomarkers for use as quality control tools.
© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  CAR T cells; artificial antigen presenting cell; authentication of biologics; cell engineering; quality control

Year:  2019        PMID: 32293122      PMCID: PMC7162992          DOI: 10.1002/adbi.201900224

Source DB:  PubMed          Journal:  Adv Biosyst        ISSN: 2366-7478


  24 in total

1.  MSC-based product characterization for clinical trials: an FDA perspective.

Authors:  Michael Mendicino; Alexander M Bailey; Keith Wonnacott; Raj K Puri; Steven R Bauer
Journal:  Cell Stem Cell       Date:  2014-02-06       Impact factor: 24.633

2.  Quality cell therapy manufacturing by design.

Authors:  Yonatan Y Lipsitz; Nicholas E Timmins; Peter W Zandstra
Journal:  Nat Biotechnol       Date:  2016-04       Impact factor: 54.908

3.  HIV-specific Immunity Derived From Chimeric Antigen Receptor-engineered Stem Cells.

Authors:  Anjie Zhen; Masakazu Kamata; Valerie Rezek; Jonathan Rick; Bernard Levin; Saro Kasparian; Irvin Sy Chen; Otto O Yang; Jerome A Zack; Scott G Kitchen
Journal:  Mol Ther       Date:  2015-06-08       Impact factor: 11.454

4.  Modular Antigen-Specific T-cell Biofactories for Calibrated In Vivo Synthesis of Engineered Proteins.

Authors:  Claire E Repellin; Puja Patel; Lucia Beviglia; Harold Javitz; Lidia Sambucetti; Parijat Bhatnagar
Journal:  Adv Biosyst       Date:  2018-09-14

Review 5.  Mesothelin targeted cancer immunotherapy.

Authors:  Raffit Hassan; Mitchell Ho
Journal:  Eur J Cancer       Date:  2007-10-22       Impact factor: 9.162

Review 6.  Folate-targeted therapeutic and imaging agents for cancer.

Authors:  Philip Stewart Low; Sumith Anurasiri Kularatne
Journal:  Curr Opin Chem Biol       Date:  2009-05-04       Impact factor: 8.822

7.  Chimeric antigen receptor (CAR)-engineered T cells redirected against hepatitis C virus (HCV) E2 glycoprotein.

Authors:  Giuseppe A Sautto; Karin Wisskirchen; Nicola Clementi; Matteo Castelli; Roberta A Diotti; Julia Graf; Massimo Clementi; Roberto Burioni; Ulrike Protzer; Nicasio Mancini
Journal:  Gut       Date:  2015-02-06       Impact factor: 23.059

8.  The challenges with the validation of research antibodies.

Authors:  Jan L A Voskuil
Journal:  F1000Res       Date:  2017-02-17

9.  Antibody validation of immunohistochemistry for biomarker discovery: recommendations of a consortium of academic and pharmaceutical based histopathology researchers.

Authors:  William J Howat; Arthur Lewis; Phillipa Jones; Caroline Kampf; Fredrik Pontén; Chris M van der Loos; Neil Gray; Chris Womack; Anthony Warford
Journal:  Methods       Date:  2014-02-11       Impact factor: 3.608

Review 10.  Garbage in, garbage out: a critical evaluation of strategies used for validation of immunohistochemical biomarkers.

Authors:  Gillian O'Hurley; Evelina Sjöstedt; Arman Rahman; Bo Li; Caroline Kampf; Fredrik Pontén; William M Gallagher; Cecilia Lindskog
Journal:  Mol Oncol       Date:  2014-03-21       Impact factor: 6.603

View more
  3 in total

1.  Lentivirus Manufacturing Process for Primary T-Cell Biofactory Production.

Authors:  Harikrishnan Radhakrishnan; Harold S Javitz; Parijat Bhatnagar
Journal:  Adv Biosyst       Date:  2020-05-10

2.  NK-Cell Biofactory as an Off-the-Shelf Cell-based Vector for Targeted In Situ Synthesis of Engineered Proteins.

Authors:  Claire E Repellin; Marvin A Ssemadaali; Sherri Newmyer; Harikrishnan Radhakrishnan; Harold S Javitz; Parijat Bhatnagar
Journal:  Adv Biol (Weinh)       Date:  2021-04-19

3.  Cell-Based Platform for Antigen Testing and Its Application for SARS-CoV-2 Infection.

Authors:  Marvin A Ssemadaali; Sherri Newmyer; Harikrishnan Radhakrishnan; Juan Arredondo; Harold S Javitz; Satya Dandekar; Parijat Bhatnagar
Journal:  Microbiol Spectr       Date:  2022-07-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.